Yongfei Chen

发表

Effect of pharmaceutical care on clinical outcomes of outpatients with type 2 diabetes mellitus

Hua Shao, Guoming Chen, Chao Zhu, 2017, Patient preference and adherence.

Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.

N. Gray, Qingsong Liu, W. Hur, 2017, European journal of medicinal chemistry.

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.

Qingsong Liu, Xiaofei Liang, Q. Liu, 2021, Journal of medicinal chemistry.

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

N. Gray, Qingsong Liu, D. McMillin, 2014, ACS chemical biology.

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

N. Gray, Qingsong Liu, Wei Wei, 2017, Scientific Reports.

An Unusual Benzoisoquinoline-9-one Derivative and Other Related Compounds with Antiproliferative Activity from Hawaiian Endophytic Fungus Peyronellaea sp. FT431

Ariel M. Sarotti, J. Turkson, Qingsong Liu, 2019, Molecules.

Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2017, European journal of medicinal chemistry.

High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis

Yun Fang, Long Meng, Yongfei Chen, 2015, Journal of chemotherapy.

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Q. Liu, Hong Wu, Zong-ru Jiang, 2023, Signal Transduction and Targeted Therapy.

Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.

Qingsong Liu, C. Yun, Zhenquan Hu, 2017, European journal of medicinal chemistry.

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

Kwok-Kin Wong, N. Gray, Qingsong Liu, 2014, Clinical Cancer Research.

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.

X. Liu, Zhenquan Hu, Q. Liu, 2020, European journal of medicinal chemistry.

Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis

Long Meng, Hua Shao, Yongfei Chen, 2013, Hypertension Research.

Discovery of a Highly Selective STK16 Kinase Inhibitor.

N. Gray, Qingsong Liu, Jinhua Wang, 2016, ACS chemical biology.

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

N. Gray, Qingsong Liu, Wei Wei, 2017, Scientific Reports.

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

N. Gray, Qingsong Liu, C. Mitsiades, 2014, Clinical Cancer Research.

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

X. Liu, M. Eck, J. Griffin, 2016, Leukemia.